BactiQuant (BACTIQ) Q1 2026 TU earnings summary

Executive summary

• Revenue in Q1 2026 reached DKK 3.3 million, representing a 29% year-over-year increase, driven by strong recurring revenue growth, especially in Pharma.

• Significant growth in consumables sales for BactiQuant Online, more than doubling compared to last year.

• First hardware sale to a major hospital in the capital region, marking entry into a new customer segment.

Financial highlights

• Q1 2026 revenue: DKK 3.3 million, up 29% from Q1 2025.

• Recurring revenue grew 71% year-over-year, while hardware sales declined 10%.

• Other revenue (accessories, service, freight) increased 41% year-over-year.

Outlook and guidance

• 2026 revenue guidance remains at DKK 10–13 million.

• 2026 EBITDA guidance is unchanged at DKK -7 to -10 million.

• Liquidity is expected to be sufficient through the end of 2027 based on current forecasts.